System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Frank Griesinger is an expert in Oncology at Pius Hospital Oldenburg (Germany). As of October 2026, ScienceLeadR ranks Frank Griesinger in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Frank Griesinger has authored 482 publications, the most recent in 2026, and is an investigator in 61 clinical trials, 21 of them ongoing. SLR score: 2,574 (community average: 125). How the SLR is computed.

LeadR Profile

Frank Griesinger Pius Hospital Oldenburg Germany
2 574 ScienceLeadR Reputation 2574

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Pius Hospital Oldenburg

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 482

Citations

Citations: 14 850 1st author: 76 Last author: 101 Unique author: 11

Main journals

J Thorac Oncol 67
Ann Oncol 66
J Clin Oncol 44
Pneumologie 37
Lung Cancer 26

Best Journals

Ann Oncol 44
J Clin Oncol 19
N Engl J Med 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).
PMID 42710416 — cells, genes, recombination, genetic, lung, poly(adp-ribose) polymerases, homologous recombination, neoplasms, poly adenosine diphosphate ribose, biomarkers, maintenance, lung neoplasms, recombinational dna repair, small cell lung carcinoma, therapeutics, etoposide, carboplatin		Clin Lung Cancer20260
FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC.
PMID 42848441 — cells, safety, carcinoma, non-small-cell lung, mutation		Clin Cancer Res20260
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
PMID 42563153 — safety, induction chemotherapy, neoplasms, decitabine, leukemia, drug therapy, leukemia, myeloid, acute, leukemia, myeloid, therapeutics, tretinoin, chemotherapy		BMC Cancer20260
Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).
PMID 42512379 — registries, cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, therapeutics		Cancers (Basel)20260
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.
PMID 42372417 — pemetrexed, mesothelioma, lung neoplasms, nivolumab, therapeutics, ipilimumab		Clin Lung Cancer20260

Clinical Studies 61

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 33
Phase 2 9
N/A 6
Phase 1 5
Phase 2/Phase 3 4
Phase 1/Phase 2 2
Phase 4 2

By status:

Completed 21
Active not recruiting 14
Recruiting 14
Terminated 5
Not yet recruiting 4
Unknown 3

By type:

Interventional 56
Observational 5

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 0
multicentricup10 56

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

21 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib		Phase 3Active not recruiting2021
DAREON Lung 1 A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab carboplatin and etoposide treatment with standard chemotherapy
2025-520565-51-00 — cells, lung, neoplasms, multiple chronic conditions, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, etoposide, carboplatin, chemotherapy		Phase 3Not yet recruiting2026
A Study of Navlimetostat (BMS 986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First line Metastatic Non small Cell Lung Cancer with Homozygous MTAP Deletion
2025-521511-40-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, chemotherapy		Phase 2/Phase 3Recruiting2025
Beamion LUNG 3 A study to test whether zongertinib helps people with surgically removed non small cell lung cancer with HER2 mutations compared with standard treatment
2025-521284-12-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation		Phase 3Not yet recruiting2026
A trial to learn how effective and safe datopotamab deruxtecan (Dato DXd) is compared to docetaxel and how well Dato DXd works in adults with advanced or metastatic TROP2 positive non squamous non small cell lung cancer (NS NSCLC)
2024-520101-39-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma		Phase 3Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS